ストックスクリーナーアプリを入手
55.58
1.87%
1.02
アフターアワーズ：
55.70
0.12
+0.22%
前日終値:
$54.56
開ける：
$54.72
24時間の取引高:
547.20K
Relative Volume:
0.76
時価総額：
$3.19B
収益：
$665.13M
当期純損益:
$64.50M
株価収益率:
48.58
EPS:
1.1442
ネットキャッシュフロー:
$185.87M
1週間 パフォーマンス:
-1.31%
1か月 パフォーマンス:
+13.24%
6か月 パフォーマンス:
+22.34%
1年 パフォーマンス:
+75.61%
1日の値動き範囲:
$54.16
$56.49
1週間の範囲:
$52.95
$56.59
52週間の値動き範囲:
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
55.58 | 3.13B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-09 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-09-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView
Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan
Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan
SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia
Supernus (NASDAQ: SUPN) CFO logs RSU vesting, stock awards and tax withholdings - Stock Titan
Director in Supernus (NASDAQ: SUPN) gets 4,475-share stock award - Stock Titan
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus (SUPN) director Carrolee Barlow granted 4,475 common shares - Stock Titan
Supernus (SUPN) CMO awarded stock as shares withheld for taxes - Stock Titan
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK
Supernus FY25 Total Revenues Up 9%; Guides 17-21% Growth For FY26 - RTTNews
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q4 2025 Earnings Conference - 富途牛牛
Supernus Pharmaceuticals Swings to Q4 Loss, Revenue Rises - marketscreener.com
Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - Sahm
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highli - GuruFocus
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Millennium Management LLC Increases Stake in Supernus Pharmaceuticals Inc. - GuruFocus
Supernus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SUPN Sets 2026 Revenue and Earnings Guidance - GuruFocus
Supernus (SUPN) Reports Strong Q4 Revenue and Outlines Future Pl - GuruFocus
Supernus: Fourth Quarter Financial Overview - Bitget
Supernus: Q4 Earnings Snapshot - marketscreener.com
Supernus boosts executive pay with new equity incentives - TipRanks
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):